Mesoblast Gain May Signal Biotech Recovery In ASX Health Stocks
The biotech industry has been hit by an unprecedented sell-off over the past year, with most equities falling by more than 50%. However, many recent market fund raises suggest that the battered sector may be on the verge of recovery. Mesoblast (AS:MSB), a market leader in the pharma stock industry, disclosed last week that it…